# Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

> **NCT03905525** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 273 (actual)

## Conditions studied

- Sjögren Syndrome

## Interventions

- **DRUG:** CFZ533
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03905525
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-01
- **Primary completion:** 2022-09-28
- **Final completion:** 2023-06-06
- **Target enrollment:** 273 (ACTUAL)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03905525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03905525, "Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT03905525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*